Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 5/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26134300 | 0.81 | HDAC3 (0.32) | TRPM8 | |
| SCHEMBL3594791 | 0.79 | GSK3B (0.39) | GSK3BCETPMT-CO2 | |
| SCHEMBL23281876 | 0.79 | GSK3B (0.39) | GSK3BDYRK1ARETGPR119MT-CO2 | |
| SCHEMBL18418860 | 0.75 | GPR119 (0.33) | GPR119 | |
| SCHEMBL27228670 | 0.74 | ALOX5AP (0.37) | GSK3BDYRK1A | |
| SCHEMBL2378220 | 0.73 | SSTR4 (0.36) | CETPUSP30 | |
| SCHEMBL16256630 | 0.72 | PAX8 (0.36) | CETPUSP30 | |
| SCHEMBL18418858 | 0.71 | LMNA (0.37) | GPR119USP30 | |
| SCHEMBL22573020 | 0.70 | TRPM8 (0.38) | GSK3BDYRK1AGPR119MT-CO2USP30 | |
| SCHEMBL22573169 | 0.70 | TRPM8 (0.38) | GSK3BDYRK1AGPR119USP30TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425482-A1 | PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-12-26 | — | — | US | disclosed |
| EP-4419516-A1 | PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-08-28 | — | — | EP | disclosed |
| CN-118284601-A | Pyrrolidine derivatives as DDR inhibitors | 奇斯药制品公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2023066834-A1 | PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023066834-A1 | PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425482-A1 | PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS | DDR1, DDR2, DDRGK1 | GSK3B 1932/4885DYRK1A 899/4885RET 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.